secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001104659-23-118241
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics reports Q3 net loss of $23.9M, advances GSBR-1290 and forms Schrödinger collaboration
--------------------------------------------------------------------------------

- Phase 1b study of GSBR-1290 showed up to 4.9% placebo-adjusted weight loss; no AE-related discontinuations.
- Topline Phase 2a T2DM data expected December 2023; obesity cohort data H1 2024; global Phase 2b planned H2 2024.
- Completed $300M private placement in October 2023; cash $205.4M at Sept 30, extending runway through 2026.
- Collaboration with Schrödinger: up to $89M milestones plus low single-digit royalties on net sales.
- Net loss $23.9M for Q3 2023 vs $12.4M in Q3 2022; R&D expenses increased to $17.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465923118241/0001104659-23-118241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465923118241/tm2329572d10_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-118241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer